UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
FORM 12b-25
SEC FILE NUMBER
000-54586
       
 
NOTIFICATION OF LATE FILING
CUSIP NUMBER

                             
(Check one):
 
 Form 10-K 
 
 Form 20-F 
 
 Form 11-K 
x
 Form 10-Q 
 
 Form 10-D 
 
 Form N-SAR 
 
 Form N-CSR
 
  For Period Ended:   March 31, 2015                                           
     
   
 Transition Report on Form 10-K
     
   
 Transition Report on Form 20-F
     
   
 Transition Report on Form 11-K
     
   
 Transition Report on Form 10-Q
     
   
 Transition Report on Form N-SAR
     
 
For the Transition Period Ended:    Not applicable                                              
   
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
PART I — REGISTRANT INFORMATION

 
BOSTON THERAPEUTICS, INC.
 
 
Full Name of Registrant.
 
     
 
Not applicable
 
 
Former Name if Applicable
 
     
 
1750 ELM STREET SUITE 103
 
 
Address of Principal Executive Office (Street and Number)
 
     
 
MANCHESTER, NH  03104
 
 
City, State and Zip Code:
 
 

 
 

 

 
 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

X
(a)
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
 
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
   
 
 
 
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 
PART III — NARRATIVE
 
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)
 
The Company is unable to complete the filing of its periodic report Form 10-Q , without unreasonable effort and expense, for the period ended March 31, 2015 within the time period prescribed.  The Company entered into four convertible promissory note agreements and a warrant agreement in March 2015, that requires extensive analysis for the accounting and disclosures to be incorporated into this quarterly report.  The Company is working towards filing its Form 10-Q within the extension period.


 
 

 

 
 
PART IV — OTHER INFORMATION

                     
(1)
Name and telephone number of person to contact in regard to this notification
 
 
Anthony D. Squeglia
 
(603)
 
935-9799
 
 
(Name)
 
(Area Code)
 
(Telephone Number)
 
 
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes 
x
No 
     
   
 
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes 
 
No 
x
   
 
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
   
   
 

         
 
BOSTON THERAPEUTICS, INC.
(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:
May 15, 2015
 
By:
/s/ Anthony D. Squeglia
       
Anthony D. Squeglia
Chief Financial Officer